United Therapeutics
UTHR
373 hedge funds and large institutions have $5.13B invested in United Therapeutics in 2017 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 125 increasing their positions, 142 reducing their positions, and 34 closing their positions.
164% more call options, than puts
Call options by funds: $69.2M | Put options by funds: $26.2M
15% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 34
0% more funds holding
Funds holding: 373 → 373 (0)
2.24% less ownership
Funds ownership: 102.79% → 100.54% (-2.2%)
12% less repeat investments, than reductions
Existing positions increased: 125 | Existing positions reduced: 142
15% less capital invested
Capital invested by funds: $6.01B → $5.13B (-$884M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| 1 |
Fidelity International
Hamilton,
Bermuda
|
+$61M |
| 2 |
Renaissance Technologies
New York
|
+$55.6M |
| 3 |
Millennium Management
New York
|
+$30.1M |
| 4 |
JIM
Jupiter Investment Management
London,
United Kingdom
|
+$28.9M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$21.1M |
Top Sellers
| 1 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
-$108M |
| 2 |
SCM
Scopia Capital Management
New York
|
-$91.5M |
| 3 |
Goldman Sachs
New York
|
-$56.3M |
| 4 |
BNP Paribas Financial Markets
Paris,
France
|
-$41.5M |
| 5 |
LSV Asset Management
Chicago,
Illinois
|
-$38.3M |
UTHR Hedge Fund Activity: Q3 2017 in Review
373 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q3 2017, worth a combined $5.13B — down 15% from $6.01B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new UTHR positions and 34 closed out — a net gain of 5 holders — while 125 added to existing stakes and 142 trimmed.
The largest buyer was Fidelity International, opening a new position worth an estimated $61M. The largest seller was AJO LP, exiting entirely with an estimated $108M sold.
- 373 institutional investors held United Therapeutics (UTHR) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $5.13B of United Therapeutics stock for Q3 2017, down 15% quarter-over-quarter.
- 39 funds opened new United Therapeutics positions in Q3 2017 and 34 closed out, a net change of +5 holders.
- The largest United Therapeutics buyer in Q3 2017 was Fidelity International, an estimated $61M added.
- The largest United Therapeutics seller in Q3 2017 was AJO LP, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2017.